Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing precisely targeted small molecule therapies for cancer patients. Leveraging chemistry and structure-based drug design, the company targets clinically proven kinase targets. Its two lead product candidates are zidesamtinib (NVL-520) for ROS1-positive NSCLC and neladalkib (NVL-655) for ALK-positive NSCLC, both designed to overcome resistance, selectivity limitations, and brain metastases challenges of existing therapies.
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-073317 | EDGAR | 113K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-028328 | EDGAR | 111K words |
| 2024-02-27 | 2023-12-31 | 0000950170-24-020607 | EDGAR | 105K words |
| 2023-03-16 | 2022-12-31 | 0000950170-23-008284 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0001193125-22-087401 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-30 | 2025-09-30 | 0001193125-25-257357 | EDGAR | 75K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104532 | EDGAR | 74K words |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066401 | EDGAR | 70K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124518 | EDGAR | 71K words |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093285 | EDGAR | 68K words |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056232 | EDGAR | 66K words |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063341 | EDGAR | 71K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-040937 | EDGAR | 69K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020807 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024138 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001193125-22-216780 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001193125-22-148022 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-15 | 0001193125-26-304126 | EDGAR | 7K words |
| 2026-02-26 | 0001193125-26-073304 | EDGAR | 2K words |
| 2026-01-14 | 0001193125-26-012243 | EDGAR | 2K words |
| 2025-12-16 | 0001193125-25-320150 | EDGAR | 1K words |
| 2025-12-10 | 0001193125-25-314165 | EDGAR | 1K words |
| 2025-11-20 | 0001193125-25-288770 | EDGAR | 1K words |
| 2025-11-17 | 0001193125-25-283893 | EDGAR | 3K words |
| 2025-10-30 | 0001193125-25-257347 | EDGAR | 2K words |
| 2025-09-22 | 0001193125-25-209934 | EDGAR | 0K words |
| 2025-08-07 | 0000950170-25-104531 | EDGAR | 2K words |
89 total filings indexed. 62 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001861560 |
| Ticker | NUVL |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.nuvalent.com |
| Listed | 2021-07-29 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/NUVL (~200 tokens, structured JSON with cryptographic provenance)